Microbiome therapeutics firm Vedanta Biosciences has established separate partnerships with researchers at Stanford University School of Medicine and at Leiden University Medical Center.
The collaboration with Stanford University’s Kari Nadeau, M.D., Ph.D., will analyze connections between the gut microbiome and responses to oral immunotherapies in children with food allergies. Professor Nadeau is director of the Sean N. Parker Center for Allergy and Asthma Research.
Vedanta’s partnership with professor Ed Kuijper M.D., Ph.D., professor of medical microbiology at Leiden University Medical Center, will derive clinical data from interventional studies of fecal transplantation in Clostridium difficile patients, from Netherlands Donor Feces Bank donors, and from studies in patients with graft-versus-host disease. Dr. Kuipjer is co-chair of the Netherlands Donor Feces Bank. Vedanta said it will feed clinical data into its in house discovery, development, and GMP manufacturing platform for rationally designed bacterial consortia treatments.
Vedanta is developing a pipeline of treatments for immune and infectious diseases based on consortia of commensal bacteria. The firm has a number of academic collaborations, and in January 2015 inked a potentially $241 million deal with the J&J subsidiary Janssen Biotech to develop a Vedanta microbiome-therapy for inflammatory bowel disease.